ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för osimertinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

48 träffar

Bibliografisk träff 2018-10-01

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.

Metro G, Baglivo S, Siggillino A, Ludovini V, Chiari R, Rebonato A, Bellezza G.

Clin Drug Investig · journal article; case reports · DOI 10.1007/s40261-018-0691-8

Bibliografisk träff 2018-09-17

Osimertinib Treats CNS Metastases in NSCLC.

Författaruppgift saknas

Cancer Discov · comment; news · DOI 10.1158/2159-8290.cd-nb2018-121

Bibliografisk träff 2018-09-07

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.

Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC.

Cancer Res Treat · clinical trial, phase ii; research-article; journal article · DOI 10.4143/crt.2018.387

Bibliografisk träff 2018-09-01

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.

Furuta H, Uemura T, Yoshida T, Kobara M, Yamaguchi T, Watanabe N, Shimizu J, Horio Y, Kuroda H, Sakao Y, Yatabe Y, Hida T.

Anticancer Res · journal article · DOI 10.21873/anticanres.12847

Bibliografisk träff 2018-08-28

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol · journal article · DOI 10.1200/jco.2018.78.3118

Bibliografisk träff 2018-08-20

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW.

Oncologist · research-article; journal article · DOI 10.1634/theoncologist.2018-0264

Bibliografisk träff 2018-08-01

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Aguiar PN, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G.

JAMA Oncol · comparative study; research-article; randomized controlled trial; journal article · DOI 10.1001/jamaoncol.2018.1395

Bibliografisk träff 2018-07-11

A case report of toxic epidermal necrolysis associated with AZD-9291.

Wang J, Cheng X, Lu Y, Zhou B.

Drug Des Devel Ther · journal article; case reports; case-report · DOI 10.2147/dddt.s168248

Bibliografisk träff 2018-07-01

Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients.

Yang B, Zheng D, Zeng Υ, Qin A, Gao J, Yu G.

J BUON · clinical trial; journal article

Bibliografisk träff 2018-04-01

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M.

Transl Lung Cancer Res · comment; editorial · DOI 10.21037/tlcr.2018.03.19

Bibliografisk träff 2017-11-18

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators.

N Engl J Med · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1713137

Bibliografisk träff 2016-04-01

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA.

JAMA Oncol · letter; clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; research support, n.i.h., extramural · DOI 10.1001/jamaoncol.2015.5009

Bibliografisk träff 2016-03-01

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Pirker R.

Curr Opin Oncol · review; journal article · DOI 10.1097/cco.0000000000000260

Bibliografisk träff 2016-02-01

Osimertinib: First Global Approval.

Greig SL.

Drugs · review; journal article · DOI 10.1007/s40265-015-0533-4

Bibliografisk träff 2015-11-30

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Shea M, Costa DB, Rangachari D.

Ther Adv Respir Dis · research support, non-u.s. gov't; review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1177/1753465815617871

Bibliografisk träff 2015-11-01

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K.

Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.5887

Bibliografisk träff 2015-10-09

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

Remon J, Planchard D.

Future Oncol · review; journal article · DOI 10.2217/fon.15.250

Bibliografisk träff 2002-12-21

Osimertinib

Författaruppgift saknas

Tidskrift saknas · review

Gå till forskningen.

Publikationer i urvalet

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.

Osimertinib Treats CNS Metastases in NSCLC.

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the <i>EGFR</i> T790M Mutation After Failure of Initial EGFR-TKI Treatment.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Osimertinib for <i>EGFR</i>-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

A case report of toxic epidermal necrolysis associated with AZD-9291.

Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients.

Osimertinib in untreated epidermal growth factor receptor (<i>EGFR</i>)-mutated advanced non-small cell lung cancer.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Osimertinib: First Global Approval.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

Osimertinib